[go: up one dir, main page]

EA200501505A1 - Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях - Google Patents

Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях

Info

Publication number
EA200501505A1
EA200501505A1 EA200501505A EA200501505A EA200501505A1 EA 200501505 A1 EA200501505 A1 EA 200501505A1 EA 200501505 A EA200501505 A EA 200501505A EA 200501505 A EA200501505 A EA 200501505A EA 200501505 A1 EA200501505 A1 EA 200501505A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
partners
inflammation
connection
application
Prior art date
Application number
EA200501505A
Other languages
English (en)
Other versions
EA009026B1 (ru
Inventor
Вэньфэн Сюй
Уэйн Киндсвогель
Ясмин А. Чандрасекер
Стейси Р. Диллон
Джойс М. Ленер
Энтони У. Сиадак
Паллавур В. Сивакумар
Маргарет Д. Мур
Original Assignee
Займоджинетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33101289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200501505(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Займоджинетикс, Инк. filed Critical Займоджинетикс, Инк.
Publication of EA200501505A1 publication Critical patent/EA200501505A1/ru
Publication of EA009026B1 publication Critical patent/EA009026B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к блокированию, ингибированию, снижению, подавлению или нейтрализации активности полипептидных молекул IL-22, IL-20 или IL-20 и IL-22. IL-20 и IL-22 являются цитокинами, которые участвуют в воспалительных процессах и в патогенезе заболевания человека. IL-22RA (zcytor11) является общим рецептором для IL-20 и IL-22. Настоящее изобретение относится к антителам против IL-22RA и к их партнерам по связыванию, а также к способам подавления IL-22 или IL-20 и IL-22 с использованием таких антител и партнеров по связыванию.
EA200501505A 2003-03-24 2004-03-24 Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях EA009026B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24
US52329503P 2003-11-17 2003-11-17
PCT/US2004/008956 WO2004085476A2 (en) 2003-03-24 2004-03-24 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (2)

Publication Number Publication Date
EA200501505A1 true EA200501505A1 (ru) 2006-06-30
EA009026B1 EA009026B1 (ru) 2007-10-26

Family

ID=33101289

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200501506A EA009124B1 (ru) 2003-03-24 2004-03-24 Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении
EA200501505A EA009026B1 (ru) 2003-03-24 2004-03-24 Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200501506A EA009124B1 (ru) 2003-03-24 2004-03-24 Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении

Country Status (16)

Country Link
US (6) US20060134756A1 (ru)
EP (2) EP1606316A2 (ru)
JP (2) JP2007525438A (ru)
KR (3) KR20050116392A (ru)
CN (2) CN103864934A (ru)
AT (1) ATE475673T1 (ru)
AU (2) AU2004223836A1 (ru)
BR (2) BRPI0408683A (ru)
CA (2) CA2519089C (ru)
DE (1) DE602004028347D1 (ru)
DK (1) DK1606317T3 (ru)
EA (2) EA009124B1 (ru)
ES (1) ES2347657T3 (ru)
MX (2) MXPA05010134A (ru)
NO (1) NO20054892L (ru)
WO (2) WO2004085475A2 (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7045498B2 (en) * 2000-08-08 2006-05-16 Zymogenetics, Inc. Soluble Zcytor11 cytokine receptors
DE60141546D1 (de) 2000-09-15 2010-04-22 Zymogenetics Inc Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
EP1531843B1 (en) 2001-12-17 2011-08-24 ZymoGenetics, Inc. Method for treating cervical cancer
WO2004085475A2 (en) * 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
EP1697418A2 (en) * 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
WO2006086396A2 (en) * 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
KR101453570B1 (ko) * 2005-12-02 2014-10-22 제넨테크, 인크. Ｉｌ-22 및 ｉｌ-22ｒ에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
CA2634262A1 (en) * 2005-12-22 2007-07-05 Dhy & Co., Ltd Antibodies against interleukin-22 binding protein and its uses
US20090305978A1 (en) * 2006-03-16 2009-12-10 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CA2700394C (en) 2007-09-26 2017-10-24 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP2241332A4 (en) 2007-12-05 2011-01-26 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST PRITURE
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
JP4954326B2 (ja) 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US8287861B2 (en) * 2008-06-30 2012-10-16 Novo Nordisk A/S Anti-human interleukin-20 antibodies
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
JP6141275B2 (ja) * 2011-08-05 2017-06-07 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ 線維症感受性ｉｌ２２ｒａ２遺伝子およびその使用
US8597647B1 (en) * 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
EP2890711B1 (en) * 2012-08-31 2017-01-04 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
EP3284480B1 (en) 2015-04-14 2025-07-02 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
EP3464357A1 (en) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US20220177912A1 (en) * 2019-04-12 2022-06-09 The Methodist Hospital Therapeutic particles that enable antigen presenting cells to attack cancer cells
US20220307035A1 (en) * 2019-06-12 2022-09-29 Acurasysbio Co., Ltd. Composition for preventing or treating cancer
IL293099B2 (en) 2019-11-20 2025-07-01 Chugai Pharmaceutical Co Ltd A preparation containing antibodies

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
EP0742830B1 (en) 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusion proteins that include antibody and nonantibody portions
JP3713074B2 (ja) * 1995-08-30 2005-11-02 栄研化学株式会社 血清アミロイドａを認識するモノクローナル抗体
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1012260A4 (en) 1997-07-16 2001-05-09 Human Genome Sciences Inc INTERLEUKINE-20
US6486301B1 (en) * 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
KR100236609B1 (ko) * 1997-08-01 2000-02-01 박호군 클로로하이드로실란 유도체 및 이의 제조방법
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2298439A1 (en) 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
PL198687B1 (pl) * 1997-11-26 2008-07-31 Zymogenetics Inc Zastosowanie polipeptydu do wytwarzania leku
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
AU737592B2 (en) 1998-01-23 2001-08-23 Immunex Corporation Il-18 receptors
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU5203199A (en) 1998-05-26 1999-12-13 Procter & Gamble Company, The Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
AU760224B2 (en) 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
JP4828703B2 (ja) 1999-04-28 2011-11-30 ジェネティックス インスティテュート エルエルシー ヒトｇｉｌ−１９／ａｅ２８９タンパク質、及び、同タンパク質をコードするポリヌクレオチド
AU5151100A (en) 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
WO2000073457A1 (en) 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
CA2372511C (en) 1999-06-15 2011-11-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1190056B1 (en) 1999-07-07 2007-04-25 ZymoGenetics, Inc. Human cytokine receptor
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2392109A1 (en) 1999-11-18 2001-05-25 Schering Corporation Mammalian receptor proteins; related reagents and methods
US6897292B2 (en) 1999-12-03 2005-05-24 Zymogenetics, Inc. Human cytokine receptor
DK1246846T3 (da) 1999-12-23 2008-12-08 Zymogenetics Inc Oplöselig interleukin-20-receptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
EP2295079A3 (en) * 1999-12-23 2011-03-23 ZymoGenetics, L.L.C. Method for treating inflammation
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) * 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
US7045498B2 (en) 2000-08-08 2006-05-16 Zymogenetics, Inc. Soluble Zcytor11 cytokine receptors
AU2001294541A1 (en) 2000-09-08 2002-03-22 Schering Corporation Mammalian genes; related reagents and methods
DE60141546D1 (de) 2000-09-15 2010-04-22 Zymogenetics Inc Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
MXPA03006218A (es) 2001-01-12 2004-09-13 Inst Genetics Llc Receptor de citosina tipo 2 y acidos nucleicos que codifican para lo mismo.
EP1390060A2 (en) 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
BR0207528A (pt) 2001-02-23 2006-01-17 Inst Genetics Llc Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2002070001A2 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
CA2439636A1 (en) 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
JP4009535B2 (ja) * 2001-03-09 2007-11-14 ザイモジェネティクス，インコーポレイティド 可溶性ヘテロダイマーサイトカイン受容体
WO2002077174A2 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
ES2334494T5 (es) * 2001-05-11 2013-05-29 Ludwig Institute For Cancer Research Ltd. Proteínas de unión específicas y usos de las mismas
WO2003035096A1 (en) 2001-10-22 2003-05-01 Eli Lilly And Company Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
EP1531843B1 (en) 2001-12-17 2011-08-24 ZymoGenetics, Inc. Method for treating cervical cancer
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
WO2004085475A2 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
CN1798768B (zh) * 2003-03-24 2013-05-08 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其应用
EP1697418A2 (en) 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation

Also Published As

Publication number Publication date
EP1606316A2 (en) 2005-12-21
EA200501506A1 (ru) 2006-06-30
EP1606317A2 (en) 2005-12-21
CA2519089A1 (en) 2004-10-07
JP2007525437A (ja) 2007-09-06
CN103864934A (zh) 2014-06-18
BRPI0408705A (pt) 2006-03-07
AU2004223837A2 (en) 2004-10-07
CA2519089C (en) 2014-12-23
US20100111948A1 (en) 2010-05-06
AU2004223837C1 (en) 2012-03-15
AU2004223836A1 (en) 2004-10-07
MXPA05010134A (es) 2005-11-16
DE602004028347D1 (de) 2010-09-09
WO2004085475A2 (en) 2004-10-07
CA2519057A1 (en) 2004-10-07
CN102690350A (zh) 2012-09-26
US20090074661A1 (en) 2009-03-19
US8163286B2 (en) 2012-04-24
KR20050116392A (ko) 2005-12-12
US20040209330A1 (en) 2004-10-21
MXPA05010136A (es) 2005-11-16
WO2004085476A3 (en) 2005-03-31
KR20050116390A (ko) 2005-12-12
JP2007525438A (ja) 2007-09-06
WO2004085476A2 (en) 2004-10-07
EP1606317B1 (en) 2010-07-28
BRPI0408683A (pt) 2006-03-28
DK1606317T3 (da) 2010-10-25
ATE475673T1 (de) 2010-08-15
NO20054892L (no) 2005-12-23
US20080233115A1 (en) 2008-09-25
AU2004223836A2 (en) 2004-10-07
ES2347657T3 (es) 2010-11-03
AU2004223837B2 (en) 2011-04-21
EA009124B1 (ru) 2007-10-26
US20120207761A1 (en) 2012-08-16
EA009026B1 (ru) 2007-10-26
WO2004085475A3 (en) 2005-07-14
AU2004223837A1 (en) 2004-10-07
KR20110091598A (ko) 2011-08-11
NO20054892D0 (no) 2005-10-21
US20060134756A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
EA200501505A1 (ru) Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях
IL182503A0 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
MA29226B1 (fr) Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
EA200800956A1 (ru) Антагонисты il-17a и il-17f и способы их использования
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
WO2004045525A3 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
ATE408624T1 (de) Verfahren zur reinigung von fsh
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
EA200600956A1 (ru) Молекулы-антагонисты цитокинов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU